STOCK TITAN
  1. Home
  2. KDMN

Kadmon Holdings (KDMN) Stock Price, News & Analysis

KDMN NASDAQ
Published by Stock Titan Data refreshed

What Changed

Price Move History

Daily moves over 5%
41 253 sessions, November 6, 2020 to November 8, 2021
Largest daily move
+71.1% close of September 8, 2021
1-year change
+197.8% closing prices, November 6, 2020 to November 8, 2021
1-month change
+7.2% closing prices, October 8, 2021 to November 8, 2021

Company Description

KDMN gained 197.8% in the 12 months to November 8, 2021. The last closing price was $9.50.

This page collects what Stock Titan holds for KDMN, including price data and latest news.

Stock Performance

Chart
$9.50
No recent trading
Last close: November 8, 2021
+197.8%
1 year to November 8, 2021
-
Market Cap
178.5M
Shares outstanding

Kadmon Holdings (KDMN) closed at $9.50 on November 8, 2021. In the 12 months to November 8, 2021, the price gained 197.8%.

See what a $1,000 investment in KDMN would be worth today

Average down calculator for KDMN

KDMN Metrics & Rankings

November 2021
+0.5%
—
2021
+128.9%
—

Price returns through November 8, 2021. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

View All
-0.11%

Kadmon Provides Business Update and Reports Third Quarter 2021 Financial Results

earnings
+1.84%

Kadmon Announces Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer's 36th Annual Meeting

+71.13%

Sanofi To Acquire Kadmon To Further Strengthen Growth of Transplant Business

acquisition
+4.13%

Kadmon Announces U.S. Availability of REZUROCK(TM) (belumosudil) for the Treatment of Patients with Chronic Graft-Versus-Host Disease (cGVHD)

+6.87%

Kadmon Provides Business Update and Reports Second Quarter 2021 Financial Results

earnings
+1.30%

Kadmon Announces REZUROCK(TM) (belumosudil) Added to National Comprehensive Cancer Network(R) Clinical Practice Guidelines in Oncology for Hematopoietic Cell Transplantation

-6.54%

Kadmon Announces Pivotal Trial Data Published in the Journal Blood for REZUROCK(TM) (Belumosudil) in Chronic Graft-Versus-Host Disease (cGVHD)

+20.56%

U.S. FDA Grants Full Approval of REZUROCK(TM) (belumosudil) for the Treatment of Patients with Chronic Graft-Versus-Host Disease (cGVHD)

fda approval
+3.54%

Kadmon to Present at Upcoming Investor Conferences

conferences
+2.40%

Kadmon to Present Initial Safety Data from Phase 1 Study of KD033 at the 2021 American Society of Clinical Oncology Annual Meeting

conferences clinical trial

Kadmon Holdings has 10 recent news articles. Of the recent coverage, 8 articles coincided with positive price movement and 2 with negative movement. Key topics include earnings, acquisition, fda approval, conferences, clinical trial. View all KDMN news →

SEC Filings

No SEC filings available for KDMN.

Frequently Asked Questions

What is the current quoted price of Kadmon Holdings (KDMN)?

Kadmon Holdings (KDMN) has no recent trading. Its last close was $9.50 on November 8, 2021.